Elise M. Weerts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elise M. Weerts has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Frances Moore
Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, USA
17 shared publications Barbara J. Kaminski
Johns Hopkins University School of Medicine, USA
15 shared publicationsRoland R. Griffiths
Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, USA
11 shared publicationsMary E. McCaul
Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
10 shared publicationsHiroto Kuwabara
Division of Radiology and Radiological Science Johns Hopkins University School of Medicine Baltimore Maryland USA
8 shared publicationsRyan Vandrey
Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, USA
8 shared publications
Latest Publications
- 25 September 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-10
The monoterpenes ⍺-pinene and limonene augment or mitigate THC-induced impairments in sustained attention in rats
- 25 September 2026
- Published by Springer Nature in Psychopharmacology
- p. 1-10
The monoterpenes ⍺-pinene and limonene augment or mitigate THC-induced impairments in sustained attention in rats
- Open Access
Chronic Δ9-Tetrahydrocannabinol Vapor Self-Administration Modulates Gut Microbiota and the Immune and Endocannabinoid Systems in Female Sprague- Dawley Rats
Vaping of cannabis and its primary components, including Δ9- tetrahydrocannabinol (THC), has increased during the last decade, especially among adolescents and adults. While the behavioral consequences of THC, including anxiety, depression, and associated impacts on reward-related signaling, are well documented, evaluation of additional pathways that have implications for neuronal function remains relatively unexplored. Further, despite evidence of the impact of THC on several physiologic processes, most studies have focused on the brain even though the endocannabinoid system with which THC interacts has widespread expression and functions throughout the body. To address these gaps, we obtained biological samples from adult female Sprague-Dawley rats (N=5-6 per group; all females) that were passively exposed to THC or vehicle vapor and then allowed to self-administer vaporized THC or vehicle intermittently for nine months. Animals were euthanized, and brain and peripheral organs were collected for analyses. We evaluated genes of endocannabinoid system-related receptors, modulators, ion channels, and metabolic enzymes, along with immune and microbiome-related pathways in 9 peripheral organs, 14 brain regions, and plasma. We observed that rats exposed to chronic intermittent THC vapor administration had widespread modulation of several endocannabinoid- system genes only in the brain, with most changes occurring in the dorsal striatum and hippocampus. In contrast, endocannabinoid-system gene expression in all evaluated peripheral organs remained unchanged after THC exposure. Similar findings occurred with immune-relevant genes, where il-1β , il-6 , ccl2 , and mx1 were modulated only in the brain while expression in peripheral organs remained unchanged. Immune system modulation following chronic THC exposure significantly elevated plasma concentrations of IL-17A, gut microbiota dysbiosis, and global changes to circulating metabolites, including several amino acids, fatty acids, aminosugar, and nucleic acids. Our findings provide, for the first time, a whole-body evaluation of the molecular effects of chronic THC exposure throughout adulthood on the endocannabinoid and immune systems that have implications for cannabinoid-related behavioral effects.
Open AccessChronic Δ9-Tetrahydrocannabinol Vapor Self-Administration Modulates Gut Microbiota and the Immune and Endocannabinoid Systems in Female Sprague- Dawley Rats
Vaping of cannabis and its primary components, including Δ9- tetrahydrocannabinol (THC), has increased during the last decade, especially among adolescents and adults. While the behavioral consequences of THC, including anxiety, depression, and associated impacts on reward-related signaling, are well documented, evaluation of additional pathways that have implications for neuronal function remains relatively unexplored. Further, despite evidence of the impact of THC on several physiologic processes, most studies have focused on the brain even though the endocannabinoid system with which THC interacts has widespread expression and functions throughout the body. To address these gaps, we obtained biological samples from adult female Sprague-Dawley rats (N=5-6 per group; all females) that were passively exposed to THC or vehicle vapor and then allowed to self-administer vaporized THC or vehicle intermittently for nine months. Animals were euthanized, and brain and peripheral organs were collected for analyses. We evaluated genes of endocannabinoid system-related receptors, modulators, ion channels, and metabolic enzymes, along with immune and microbiome-related pathways in 9 peripheral organs, 14 brain regions, and plasma. We observed that rats exposed to chronic intermittent THC vapor administration had widespread modulation of several endocannabinoid- system genes only in the brain, with most changes occurring in the dorsal striatum and hippocampus. In contrast, endocannabinoid-system gene expression in all evaluated peripheral organs remained unchanged after THC exposure. Similar findings occurred with immune-relevant genes, where il-1β , il-6 , ccl2 , and mx1 were modulated only in the brain while expression in peripheral organs remained unchanged. Immune system modulation following chronic THC exposure significantly elevated plasma concentrations of IL-17A, gut microbiota dysbiosis, and global changes to circulating metabolites, including several amino acids, fatty acids, aminosugar, and nucleic acids. Our findings provide, for the first time, a whole-body evaluation of the molecular effects of chronic THC exposure throughout adulthood on the endocannabinoid and immune systems that have implications for cannabinoid-related behavioral effects.
- 25 August 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1877-1888
Beyond head-twitch response: Acute psilocybin affects spontaneous behaviors in rats in a dose-dependent manner
Background: Psychedelics have emerged as promising pharmacological agents for treating a range of neuropsychiatric disorders. While preclinical studies have provided valuable insight into the neural mechanisms underlying their effects, systematic characterization of psychedelic effects on inherent spontaneous behaviors in animal models remains limited. Methods: In the current study, male and female Sprague-Dawley rats were administered psilocybin (0.5, 1, 1.5 mg/kg, i.p.) or its vehicle (saline). Behaviors were video recorded for subsequent analysis. In addition to the widely studied head-twitch response and wet dog shakes (HTR/WDS), five additional spontaneous behaviors that were modulated by psilocybin (immobility, rearing, grooming, sniffing/digging, and circling) were assessed. Results: Assessed behaviors showed distinct dose-response profiles in both sexes. When compared to saline, psilocybin elicited HTR/WDS following a bell-shaped curve, while immobility increased linearly, with dose. Rearing and grooming decreased markedly even at low doses, sniffing/digging declined only at higher doses, and circling increased variably across doses for each sex. Furthermore, some behaviors were correlated in a dose-dependent manner. Conclusion: Together, our findings highlight a broader range of behaviors influenced by psilocybin beyond HTR and provide a framework for identifying its neurobehavioral effects in Sprague-Dawley rats within a widely used physiologically relevant dose range.
- 25 August 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (11) , 1877-1888
Beyond head-twitch response: Acute psilocybin affects spontaneous behaviors in rats in a dose-dependent manner
Background: Psychedelics have emerged as promising pharmacological agents for treating a range of neuropsychiatric disorders. While preclinical studies have provided valuable insight into the neural mechanisms underlying their effects, systematic characterization of psychedelic effects on inherent spontaneous behaviors in animal models remains limited. Methods: In the current study, male and female Sprague-Dawley rats were administered psilocybin (0.5, 1, 1.5 mg/kg, i.p.) or its vehicle (saline). Behaviors were video recorded for subsequent analysis. In addition to the widely studied head-twitch response and wet dog shakes (HTR/WDS), five additional spontaneous behaviors that were modulated by psilocybin (immobility, rearing, grooming, sniffing/digging, and circling) were assessed. Results: Assessed behaviors showed distinct dose-response profiles in both sexes. When compared to saline, psilocybin elicited HTR/WDS following a bell-shaped curve, while immobility increased linearly, with dose. Rearing and grooming decreased markedly even at low doses, sniffing/digging declined only at higher doses, and circling increased variably across doses for each sex. Furthermore, some behaviors were correlated in a dose-dependent manner. Conclusion: Together, our findings highlight a broader range of behaviors influenced by psilocybin beyond HTR and provide a framework for identifying its neurobehavioral effects in Sprague-Dawley rats within a widely used physiologically relevant dose range.
- 11 July 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (8) , 104984
Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults
- 11 July 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (8) , 104984
Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults
- 26 January 2026
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (5) , 979
Nancy Almand Ator, Ph.D. 1944–2025
- 26 January 2026
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (5) , 979
Nancy Almand Ator, Ph.D. 1944–2025
- 12 January 2026
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 34 (4) , 408-416
Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats.
Opioid use disorder remains a public health crisis in the United States. A key factor in continued use, relapse risk, and overdose is the severe withdrawal syndrome that accompanies abstinence. Observational studies suggest cannabis may improve outcomes for patients with opioid use disorder and cannabidiol (CBD), a nonintoxicating compound found in cannabis, is being investigated as a potential treatment. This study investigated whether CBD alleviated withdrawal symptoms in a rat model of opioid dependence. Sprague-Dawley rats (N = 100, 50% female) were administered escalating doses of morphine across 10 days (10-50 mg/kg, twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to Day 7) timepoints. Rats were treated daily with oral CBD (10 or 30 mg/kg, p.o.) or sesame oil vehicle, beginning 14-hr after their final morphine or saline injection. Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), pain sensitivity, and measurements of anxiety-like behaviors in the protracted phase. Compared to nondependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). In the protracted phase, limited withdrawal signs and no anxiety-like behaviors were detected. Oral CBD did not affect symptoms of opioid withdrawal. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- 12 January 2026
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 34 (4) , 408-416
Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats.
Opioid use disorder remains a public health crisis in the United States. A key factor in continued use, relapse risk, and overdose is the severe withdrawal syndrome that accompanies abstinence. Observational studies suggest cannabis may improve outcomes for patients with opioid use disorder and cannabidiol (CBD), a nonintoxicating compound found in cannabis, is being investigated as a potential treatment. This study investigated whether CBD alleviated withdrawal symptoms in a rat model of opioid dependence. Sprague-Dawley rats (N = 100, 50% female) were administered escalating doses of morphine across 10 days (10-50 mg/kg, twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to Day 7) timepoints. Rats were treated daily with oral CBD (10 or 30 mg/kg, p.o.) or sesame oil vehicle, beginning 14-hr after their final morphine or saline injection. Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), pain sensitivity, and measurements of anxiety-like behaviors in the protracted phase. Compared to nondependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). In the protracted phase, limited withdrawal signs and no anxiety-like behaviors were detected. Oral CBD did not affect symptoms of opioid withdrawal. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- 17 December 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 278, 113007
Evaluation of suvorexant effects on alcohol seeking and self-administration in baboons
- 17 December 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 278, 113007
Evaluation of suvorexant effects on alcohol seeking and self-administration in baboons
- 25 November 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 243 (5) , 1283-1294
Effects of sex and pre-exposure on Δ9-tetrahydrocannabinol (THC) vapor self-administration in rats
Rationale Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of humans who use cannabis do so by inhalation (e.g., smoking, vaporization). Methods Adult male and female Sprague Dawley rats (N = 96, 6–12 per sex/group) were pre-exposed to vaporized THC or vehicle (Veh; 100% propylene glycol). Rats were then trained to self-administer vapor puffs of either THC (50 mg/ml training dose) or Veh under a fixed ratio (FR) 1 schedule. Responding was then assessed under increasing response costs (FR1-5) and different ‘doses’ (50–200 mg/ml) of THC. As a secondary study aim, we assessed the effects of pre-exposure to THC (or Veh) on self-administration of THC vapor or Veh vapor. Results There were no differences in responding for THC and Veh vapor under an FR1 schedule. As the FR increased, rats increased their responses for THC, and female rats in the THC group responded more than female rats in the Veh vapor group. When the THC concentration was increased or decreased from the training dose, rats self-administering THC vapor adjusted their responding. THC vapor pre-exposure significantly increased self-administration of THC vapor. Conclusions Adult male and female rats self-administered THC vapor in a sustained manner across several months. Rats increased their responding to obtain THC vapor as the response cost increased and titrated their THC intake based on the THC concentration available. These data demonstrate sex differences in THC vapor reinforcement and that lower THC doses and THC pre-exposure are critical for engendering the reinforcing effects of THC vapor. This is a promising model of THC vapor self-administration.
- 25 November 2025
- Published by Springer Nature in Psychopharmacology
- Vol. 243 (5) , 1283-1294
Effects of sex and pre-exposure on Δ9-tetrahydrocannabinol (THC) vapor self-administration in rats
Rationale Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of humans who use cannabis do so by inhalation (e.g., smoking, vaporization). Methods Adult male and female Sprague Dawley rats (N = 96, 6–12 per sex/group) were pre-exposed to vaporized THC or vehicle (Veh; 100% propylene glycol). Rats were then trained to self-administer vapor puffs of either THC (50 mg/ml training dose) or Veh under a fixed ratio (FR) 1 schedule. Responding was then assessed under increasing response costs (FR1-5) and different ‘doses’ (50–200 mg/ml) of THC. As a secondary study aim, we assessed the effects of pre-exposure to THC (or Veh) on self-administration of THC vapor or Veh vapor. Results There were no differences in responding for THC and Veh vapor under an FR1 schedule. As the FR increased, rats increased their responses for THC, and female rats in the THC group responded more than female rats in the Veh vapor group. When the THC concentration was increased or decreased from the training dose, rats self-administering THC vapor adjusted their responding. THC vapor pre-exposure significantly increased self-administration of THC vapor. Conclusions Adult male and female rats self-administered THC vapor in a sustained manner across several months. Rats increased their responding to obtain THC vapor as the response cost increased and titrated their THC intake based on the THC concentration available. These data demonstrate sex differences in THC vapor reinforcement and that lower THC doses and THC pre-exposure are critical for engendering the reinforcing effects of THC vapor. This is a promising model of THC vapor self-administration.
- Open Access
Effects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats
Opioid use disorder (OUD) remains a public health crisis in the United States. A key factor in continued use, relapse risk, and overdose is the severe withdrawal syndrome that accompanies abstinence. Observational studies suggest cannabis may improve outcomes for patients with OUD. Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is being investigated as a potential treatment for OUD. This study investigated whether CBD alleviated withdrawal symptoms in a rat model of opioid dependence. Sprague Dawley rats (N = 100, 50% female) were administered escalating doses of morphine across 10 days (10–50 mg/kg, s.c., twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to day 7) timepoints. Rats were treated with pure CBD (10 or 30 mg/kg, p.o.) or vehicle (sesame oil; 1 mg/ml) daily, beginning 14-hrs after their final morphine or saline injection (n = 8-9 per sex/group). Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), and pain sensitivity, as well as measurements of anxiety-like behaviors in the protracted phase. Compared to non-dependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). Oral CBD did not affect physical symptoms of opioid withdrawal nor protracted anxiety-like behaviors. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. Public health significance: This study suggests that daily oral treatment with pure CBD at doses available to consumers does not improve physical or psychological symptoms of withdrawal from chronic opioids.
Open AccessEffects of oral cannabidiol (CBD) on spontaneous opioid withdrawal in male and female rats
Opioid use disorder (OUD) remains a public health crisis in the United States. A key factor in continued use, relapse risk, and overdose is the severe withdrawal syndrome that accompanies abstinence. Observational studies suggest cannabis may improve outcomes for patients with OUD. Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is being investigated as a potential treatment for OUD. This study investigated whether CBD alleviated withdrawal symptoms in a rat model of opioid dependence. Sprague Dawley rats (N = 100, 50% female) were administered escalating doses of morphine across 10 days (10–50 mg/kg, s.c., twice daily). Following abrupt discontinuation, withdrawal outcomes were evaluated across acute (38-hr) and protracted (up to day 7) timepoints. Rats were treated with pure CBD (10 or 30 mg/kg, p.o.) or vehicle (sesame oil; 1 mg/ml) daily, beginning 14-hrs after their final morphine or saline injection (n = 8-9 per sex/group). Withdrawal severity was assessed through physical measurements of body weight, food intake, and somatic signs (e.g., body shakes, diarrhea), and pain sensitivity, as well as measurements of anxiety-like behaviors in the protracted phase. Compared to non-dependent controls, morphine-dependent rats had decreased body weight and food intake, showed greater somatic signs, and had increased pain sensitivity that peaked in acute withdrawal (38-hr). Oral CBD did not affect physical symptoms of opioid withdrawal nor protracted anxiety-like behaviors. These data indicate that CBD alone may have limited effectiveness for treating opioid withdrawal. Reports of improved withdrawal symptoms after cannabis use may be attributed to other compounds in cannabis. Public health significance: This study suggests that daily oral treatment with pure CBD at doses available to consumers does not improve physical or psychological symptoms of withdrawal from chronic opioids.
- Open Access
Effects of sex and pre-exposure on Δ9-tetrahydrocannabinol (THC) vapor self-administration in rats
Rationale: Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of human cannabis user do so by inhalation (e.g., smoking, vaporization). Methods: Adult male and female Sprague Dawley rats (N=96, 6-12 per sex/group) were pre-exposed to vaporized THC or vehicle (Veh; 100% propylene glycol). Rats were then trained to self-administer vapor puffs of either THC (50 mg/ml training dose) or Veh under a fixed ratio (FR) 1 schedule. Responding was then assessed under increasing response costs (FR1-5) and different ‘doses’ (50-200 mg/ml) of THC. As a secondary study aim, we assessed the effects of pre-exposure to THC (or Veh) on self-administration of THC vapor or Veh vapor. Results: There were no differences in responding for THC and Veh vapor under an FR1 schedule. As the FR increased, rats increased their responses for THC, and female rats in the THC group responded more than female rats in the Veh vapor group under FR4-5 schedules. When THC concentration was varied, rats titrated their intake in a predictable U-shaped pattern. THC vapor pre-exposure significantly increased self-administration of THC vapor, but not Veh vapor. Conclusions: Male and female rats voluntarily administered THC vapor in a sustained manner across several months, replicating what has been shown with vaporized cannabis extracts male rats. This study is the first to demonstrate that THC vapor has reinforcing properties in female rats and that pre-exposure is critical for engendering higher intake. This is a promising model of voluntary THC vapor administration.
Open AccessEffects of sex and pre-exposure on Δ9-tetrahydrocannabinol (THC) vapor self-administration in rats
Rationale: Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of human cannabis user do so by inhalation (e.g., smoking, vaporization). Methods: Adult male and female Sprague Dawley rats (N=96, 6-12 per sex/group) were pre-exposed to vaporized THC or vehicle (Veh; 100% propylene glycol). Rats were then trained to self-administer vapor puffs of either THC (50 mg/ml training dose) or Veh under a fixed ratio (FR) 1 schedule. Responding was then assessed under increasing response costs (FR1-5) and different ‘doses’ (50-200 mg/ml) of THC. As a secondary study aim, we assessed the effects of pre-exposure to THC (or Veh) on self-administration of THC vapor or Veh vapor. Results: There were no differences in responding for THC and Veh vapor under an FR1 schedule. As the FR increased, rats increased their responses for THC, and female rats in the THC group responded more than female rats in the Veh vapor group under FR4-5 schedules. When THC concentration was varied, rats titrated their intake in a predictable U-shaped pattern. THC vapor pre-exposure significantly increased self-administration of THC vapor, but not Veh vapor. Conclusions: Male and female rats voluntarily administered THC vapor in a sustained manner across several months, replicating what has been shown with vaporized cannabis extracts male rats. This study is the first to demonstrate that THC vapor has reinforcing properties in female rats and that pre-exposure is critical for engendering higher intake. This is a promising model of voluntary THC vapor administration.